Lifestyle
Archived — This article has been archived. The information may be outdated.
India lung trials study screening beyond smoking
Devex··11 Aug
AIIMS-led projects funded by the Bristol Myers Squibb Foundation are testing lung cancer screening beyond smoking history. AIRCARE follows about 3,200 Delhi NCR participants on PM2.5 risk. The Indian Lung Screening Trial will screen 1,716 people across 10 institutions with low-dose CT. About 40 to 50 percent of India lung cancer patients are never-smokers. Cases often appear a decade earlier.
Prism
What It Means For You
- Never-smokers in polluted cities can note that current screening rules may not yet answer whether they should seek LDCT.
- Patients and families can track AIIMS-led AIRCARE and the Indian Lung Screening Trial for India-specific risk evidence.
- Anyone following cancer policy can watch how local data may later shape national screening eligibility.
What's Happening
- Sponsored reporting describes two BMS Foundation-funded AIIMS projects on lung cancer risk beyond smoking.
- AIRCARE studies about 3,200 Delhi NCR participants; the Indian Lung Screening Trial plans LDCT for 1,716 people across 10 institutions.
- Reports say 40 to 50 percent of lung cancer patients in India are never-smokers, with earlier average presentation.
When Smoking History Alone Misses India's Risk Profile
- Landmark US and Dutch-Belgian trials set smoker-focused LDCT rules that many countries still follow.
- Air pollution is estimated to drive about 14 percent of lung cancers globally, with India's PM2.5 burden still being quantified.
- Researchers abroad have already sought to replicate the India trials after registration on clinical databases.
all-newseditors-picks
